These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. Nakamura K; Honda K; Mizutani T; Akiho H; Harada N World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430 [TBL] [Abstract][Full Text] [Related]
9. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Danese S; Panés J Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794 [TBL] [Abstract][Full Text] [Related]
10. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013 [TBL] [Abstract][Full Text] [Related]
11. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. Sands BE Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349 [TBL] [Abstract][Full Text] [Related]
13. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Van Assche G; Rutgeerts P Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604 [TBL] [Abstract][Full Text] [Related]
14. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589 [TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Jovani M; Danese S Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911 [TBL] [Abstract][Full Text] [Related]
17. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645 [TBL] [Abstract][Full Text] [Related]
18. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Lanzarotto F; Carpani M; Chaudhary R; Ghosh S Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596 [TBL] [Abstract][Full Text] [Related]